Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I)

W J Martin1, E C Rosenow

  • 1Mayo Clinic, Rochester, Minnesota 55905.

Chest
|May 1, 1988
PubMed

Insights

Early recognition of amiodarone pulmonary toxicity (APT) in patients is crucial. Prompt diagnosis and individualized treatment can prevent permanent lung damage from this cardiac drug.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Amiodarone is a key treatment for cardiac arrhythmias.
  • A significant percentage of patients (5-10%) develop amiodarone pulmonary toxicity (APT).
  • APT can lead to irreversible pulmonary function loss.

Purpose of the Study:

  • To emphasize the importance of early APT recognition.
  • To guide clinicians in diagnosing and managing amiodarone-induced lung injury.
  • To highlight the need for individualized risk-benefit assessment.

Main Methods:

  • Review of clinical data and treatment protocols for amiodarone use.
  • Analysis of diagnostic strategies for amiodarone pulmonary toxicity.
  • Evaluation of therapeutic interventions and their outcomes.

Main Results:

  • Early identification of APT is linked to better patient outcomes.
  • Individualized diagnostic and therapeutic approaches are essential.
  • Ongoing risk-benefit reevaluation is critical for patient management.

Conclusions:

  • Timely diagnosis of amiodarone pulmonary toxicity can prevent permanent lung damage.
  • Personalized management strategies are vital for patients on amiodarone.
  • Further research is needed to enhance early detection and reversibility of APT.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Pulmonary Edema II: Pathophysiology01:18

Pulmonary Edema II: Pathophysiology

Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...